Chinese biotech companies have made enormous progress in recent years, but they still need one thing: the United States.
Credit: NASDAQ
This summer, a young Chinese biotech company made a big purchase. BeiGene, which is headquartered in both Beijing and Cambridge, announced its plans for a new 42-acre research and development campus in Hopewell, NJ, about seven miles west of Princeton University. The company, which specializes in anti-cancer treatments and already has a presence in Ridgefield Park, NJ, said the new space would allow it to recruit hundreds of new hires from the area’s “deep talent pool” as well as sharpen i
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from David Barboza, Pulitzer Prize-winning former Shanghai correspondent for The New York Times.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
In 2021, after four decades of exponential growth in China’s economy, Xi Jinping revived the party slogan “common prosperity” in order to address the country’s glaring inequality. The policy priority was suddenly everywhere: in speeches, in newspapers and in schools. But now, three years later, it has all but disappeared from public discourse even as the country’s economic inequality festers. What happened?
The researcher and former OpenAI board member discusses who holds the advantage in artificial intelligence and the chances of the U.S. and China working together to regulate the technology.
On-Demand Webinar: Strategies for Identifying Military End Users
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy
